Yunfeng Li

Yunfeng Li

Auto-generated profile, based on publicly available information

Yunfeng Li

Department of Cardiology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
YLYunfeng Li
Yunfeng Li
YMYulong Ma
Yulong Ma
LYLei Yao
Lei Yao
JLJianhua Li
Jianhua Li
XZXunjie Zhou
Xunjie Zhou
DFDeyu Fu
Deyu Fu
The global epidemic of obesity and diabetes imposes a significant strain on healthcare systems, substantially elevating the risk of vascular dysfunction and its associated complications. Astragaloside IV (AS-IV) and berberine (BBR) have demonstrated considerable promise in addressing vascular issues linked to these conditions. This review examines the mechanisms driving their vascular protective effects, drawing on evidence from preclinical studies to compare and contrast their modes of action. It explores both the unique and overlapping pathways through which they mitigate the complications of obesity and diabetes. A thorough analysis of their therapeutic potential highlights promising preclinical data and its clinical implications. However, challenges remain, such as enhancing the bioavailability of AS-IV and BBR and translating preclinical findings into robust clinical trials. This synthesis provides critical insights for advancing research and practical approaches in managing vascular dysfunction associated with obesity and diabetes.